Abiomed's Impella(R) Technology Showcased at EuroPCR 2014

DANVERS, Mass., May 19, 2014 (GLOBE NEWSWIRE) -- Abiomed Inc. ABMD, a leading provider of breakthrough heart support technologies, notes that there will be approximately eight potential Impella-related presentations in the scientific sessions at the annual EuroPCR 2014 cardiovascular course, scheduled from May 20 - 23, 2014 at the Palais Des Congrès de Paris.

New this year at EuroPCR, Abiomed will have demonstrations of the Impella RP, which recently received the CE Mark, and new simulators demonstrating bi-ventricular support of the Impella platform, which can be seen at Abiomed booth #M68.

For further information about EuroPCR related to Impella and the timing of scientific presentations, please contact Aimee Genzler, Corporate Communications Manager, at agenzler@abiomed.com or 978-646-1553.

ABOUT ABIOMED

Based in Danvers, Massachusetts, Abiomed, Inc., is a leading provider of medical devices that provide circulatory support. Our products are designed to enable the heart to rest by improving blood flow and/or performing the pumping of the heart. For additional information please visit: www.abiomed.com.

FORWARD-LOOKING STATEMENTS

This release contains forward-looking statements, including statements regarding development of Abiomed's existing and new products, the Company's progress toward commercial growth, and future opportunities and expected regulatory approvals. The Company's actual results may differ materially from those anticipated in these forward-looking statements based upon a number of factors, including uncertainties associated with development, testing and related regulatory approvals, including the potential for future losses, complex manufacturing, high quality requirements, dependence on limited sources of supply, competition, technological change, government regulation, litigation matters, future capital needs and uncertainty of additional financing, and other risks and challenges detailed in the Company's filings with the Securities and Exchange Commission, including the most recently filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q. Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events.